Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-12-03
2010-02-23
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S054000, C536S122000
Reexamination Certificate
active
07666845
ABSTRACT:
The invention is directed to compounds of the formula (I) described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and pharmaceutical compositions and methods of treatment.
REFERENCES:
patent: 5424406 (1995-06-01), Tsujihara et al.
patent: 5731292 (1998-03-01), Tsujihara et al.
patent: 5830873 (1998-11-01), Tsujihara et al.
patent: 6414126 (2002-07-01), Ellsworth et al.
patent: 6515117 (2003-02-01), Ellsworth et al.
patent: 6562791 (2003-05-01), Maurya et al.
patent: 2001/0041674 (2001-11-01), Tomiyama et al.
patent: 2002/0052326 (2002-05-01), Washburn
patent: 2002/0111315 (2002-08-01), Washburn et al.
patent: 2003/0064935 (2003-04-01), Gougoutas
patent: 2003/0087843 (2003-05-01), Washburn
patent: 2003/0114390 (2003-06-01), Washburn et al.
patent: 2004/0053855 (2004-03-01), Fujikura et al.
patent: 2004/0063646 (2004-04-01), Fujikura et al.
patent: 2004/0110936 (2004-06-01), Ohsumi et al.
patent: 2004/0116357 (2004-06-01), Fushimi et al.
patent: 2004/0132669 (2004-07-01), Nishimura et al.
patent: 2004/0138143 (2004-07-01), Glombik et al.
patent: 2004/0259819 (2004-12-01), Frick et al.
patent: 2005/0014704 (2005-01-01), Frick et al.
patent: 2005/0032711 (2005-02-01), Patel et al.
patent: 2005/0032712 (2005-02-01), Urbanski
patent: 2005/0037980 (2005-02-01), Rybczynski et al.
patent: 2005/0037981 (2005-02-01), Beavers et al.
patent: 2005/0233988 (2005-10-01), Nomura et al.
patent: 2006/0035841 (2006-02-01), Eckhardt et al.
patent: 2006/0122126 (2006-06-01), Imamura et al.
patent: 2006/0217323 (2006-09-01), Patel et al.
patent: 2006/0229260 (2006-10-01), Rybczynski et al.
patent: 2006/0234954 (2006-10-01), Urbanski
patent: 2006/0293251 (2006-12-01), Urbanski et al.
patent: 2007/0060545 (2007-03-01), Nomura et al.
patent: 2008/0027122 (2008-01-01), Nomura et al.
patent: 2 494 177 (2004-02-01), None
patent: 1 528 066 (2005-05-01), None
patent: 2001-288178 (2001-10-01), None
patent: 2003-12686 (2003-01-01), None
patent: WO 01/27128 (2001-04-01), None
patent: WO 01/68660 (2001-09-01), None
patent: WO 01/74834 (2001-10-01), None
patent: WO 01/74835 (2001-10-01), None
patent: WO 02/053573 (2002-07-01), None
patent: WO 02/068439 (2002-09-01), None
patent: WO 02/068440 (2002-09-01), None
patent: WO 02/083066 (2002-10-01), None
patent: WO 02/088157 (2002-11-01), None
patent: WO 03/011880 (2003-02-01), None
patent: WO 03/020737 (2003-03-01), None
patent: WO 03/099836 (2003-12-01), None
patent: WO 2004/007517 (2004-01-01), None
patent: WO 2004/013118 (2004-02-01), None
patent: WO 2004/014931 (2004-02-01), None
patent: WO 2004/019958 (2004-03-01), None
patent: WO 2004/052903 (2004-06-01), None
patent: WO 2004/080990 (2004-09-01), None
patent: WO 2005/012326 (2005-02-01), None
patent: WO 2006/010557 (2006-02-01), None
patent: WO 2008/013322 (2008-01-01), None
Unger et al. “Hyperglycemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes” Diabetologia, vol. 28, p. 119-121 (1985).
Rossetti et al. “Glucose Toxicity”; Diabetes Care, vol. 13, p. 610-630 (1990).
Rossetti et al. Correction of Hyperglycemia with Phlorizin Normalizes Tissue Sensitivity to Insulin in diabetic rats Journal of Clinical Investigation, vol. 79, p. 1510-1515 (1987).
Rossetti et al. Effect of Chronic Hyperglycemia on In Vivo Insulin Secretion in Partially Pancreatectomized Rats Journal of Clinical Investigation, vol. 80, p. 1037-1044 (1987).
Kahn et al. “Normalization of Blood Glucose in Diabetic Rats with Phlorizin Treatment Reverses Insulin-resistant Glucose Transport in Adipose Cells without Restoring Glucose Transporter Gene Expression” Journal of Clinical Investigation, vol. 87, p. 561-570 (1991).
Tsujihara et al. “Na+ Glucose Cotransporter (SGLT) Inhibitors as Antidiabetic Agents. 4. Synthesis and Pharmacological Properties of 4′-Dehydroxyphlorizin Derivatives Substituted on the B Ring” Journal of Medicinal Chemistry, vol. 42, p. 5311-5324 (1999).
Arakawa et al, Improved diabetic syndrome in C57BL/KsJ-db/db Mice By Oral Administration of the Na+− Glucose Cotransporter Inhibitor T-1095: British Journal of Pharmacology, vol. 132, p. 578-586 (2001).
Ueta et al. “Long-term treatment with the Na+−glucose contransporter inhibitor T1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats” Life Sci., 76(23): 2655-68 (2005), etc.
Roshan Ahmad et al., Nucleosides, Nucleotides & Nucleic Acids, vol. 20, No. 9, (2001), pp. 1671-1682.
Khosrow Zamani et al., Journal of the Chinese Chemical Society, vol. 49, (2002), pp. 1041-1044.
Galal T. Maatooq et al., Phytochemistry, vol. 44, No. 1, (Jan. 1997), pp. 187-190.
Hongu et al., Chem. Pharm. Bull, vol. 46, No. 1, pp. 22-33, (1998).
PCT International Search Report dated Apr. 16, 2008 for PCT/US2007/086247 which relates to U.S. Appl. No. 11/949,236.
Baumann Christian Andrew
Cook Kevin L.
Lim Heng-Keang
Scott Lorraine
Villani Frank J.
Janssen Pharmaceutica N.V.
Jiang Shaojia Anna
Schmidtmann Bahar
LandOfFree
Compounds having inhibitory activity against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds having inhibitory activity against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds having inhibitory activity against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4196893